Newsletter Subscription

Enter Name and Email

23 January 2014 - Just published: pharmacology of a novel drug for BPSD: ADN-1184

The aging populations in western countries is drawing attention to the need for novel drug therapies to treat Behavioral and Psychological Symptoms of Dementia (BPSD). Current pharmacotherapies employ antipsychotic drugs that fail to significantly attenuate mood deficits, may interfere with cognitive function and are associated with motor and cardiac side-effects which are problematic in elderly patients.

The present publication characterises the pharmacological activity of ADN-1148, a novel ligand with marked affinity and antagonist properties at serotonin 5-HT6 and 5-HT7 receptors. ADN-1184 combines antipsychotic-like with antidepressant-like properties without interfering with memory function or locomotion. This profile is superior to that of commonly-used atypical antipsychotics and suggests that it is feasible to identify drugs that improve behavioural and psychological symptoms without exacerbating cognitive deficit or movement impairment which are of particular concern in dementia patients.

Adrian Newman-Tancredi has extensive experience of drug discovery of novel antidepressants and antipsychotics. For more information, Contact.


ADN-1184 a monoaminergic ligand with 5-HT6/7 receptor antagonism: pharmacological profile and potential therapeutic utility.
Kołaczkowski M, Mierzejewski P, Bieńkowski P, Wesołowska A, Newman-Tancredi A.
Br J Pharmacol. 2013 Nov 6. doi: 10.1111/bph.12509. [Epub ahead of print]